All Stories

  1. Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop?

    Article • Gut, September 2019, BMJ

    Professor Thomas Berg

  2. Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients

    Article • Liver International, October 2018, Wiley

    Professor Thomas Berg

  3. A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B

    Article • Alimentary Pharmacology & Therapeutics, July 2018, Wiley

    Professor Thomas Berg, Dr Mangia Alessandra

  4. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment

    Article • Hepatology, April 2018, Wiley

    Professor Thomas Berg

  5. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B

    Article • Liver International, February 2018, Wiley

    Professor Thomas Berg

  6. Less can be more - a finite treatment approach for HBeAg-negative chronic hepatitis B

    Article • Hepatology, January 2018, Wiley

    Professor Thomas Berg

  7. Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting

    Article • Scandinavian Journal of Gastroenterology, October 2017, Taylor & Francis

    Professor Thomas Berg

  8. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

    Article • Hepatology, October 2017, Wiley

    Professor Thomas Berg

  9. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis

    Article • Alimentary Pharmacology & Therapeutics, September 2017, Wiley

    Professor Thomas Berg

  10. N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury

    Article • Liver International, September 2017, Wiley

    Professor Thomas Berg

  11. Effects of stepped psychooncological care on referral to psychosocial services and emotional well-being in cancer patients: A cluster-randomized phase III trial

    Article • Psycho-Oncology, July 2017, Wiley

    Professor Thomas Berg

  12. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry

    Article • Journal of Viral Hepatitis, May 2017, Wiley

    Professor Thomas Berg

  13. The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B

    Article • Hepatology, April 2017, Wiley

    Professor Thomas Berg, Prof Henry LY Chan, Dr Mangia Alessandra

  14. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection

    Article • Alimentary Pharmacology & Therapeutics, January 2017, Wiley

    Professor Thomas Berg

  15. Flares during long-term entecavir therapy in chronic hepatitis B

    Article • Journal of Gastroenterology and Hepatology, November 2016, Wiley

    Professor Thomas Berg, teresa santantonio

  16. Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type

    Article • Journal of Viral Hepatitis, June 2016, Wiley

    Professor Thomas Berg

  17. Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders

    Article • Liver International, April 2015, Wiley

    Professor Thomas Berg

  18. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors

    Article • Hepatology, November 2014, Wiley

    Professor Thomas Berg

  19. Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study

    Article • Liver International, November 2014, Wiley

    Professor Thomas Berg, Professor Eric J Lawitz